LifeMine Therapeutics raises $263M across Series D and E rounds to advance LIFE-001, a fungal-derived calcineurin inhibitor for transplant patients.
LifeMine Therapeutics has hauled in $263 million across two venture rounds as it seeks to test a potentially safer, more convenient immunosuppressant in transplant patients.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely…
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
Full-Life Technologies gets $150M; Quince finds a new life; China biotech gets $50M; SERB Pharmaceuticals buys rights to Hansa…
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech…
The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of…
Shanghai-based Immunocan has closed a RMB250 million Series A round led by Vivo Capital, with participation from Gold Mine Multi…
